Alphatec is projected to report Q2 2026 consensus revenue of $211.3 million and an adjusted EPS of $0.09, with the current $9.56 share price trading at a significant discount to the $17.29 average analyst target.
Investors are primarily focused on the company's progress toward sustained profitability and potential updates to its full-year 2026 revenue guidance.
After missing revenue expectations in the first quarter, the market is closely monitoring surgical volume growth and the performance of the lateral surgery platform. Execution on the path to positive free cash flow remains a critical catalyst for a stock that has seen recent price target reductions due to top-line concerns.